| *Disseminated on behalf of Medicus Pharma Ltd.
(Nasdaq: MDCX) Is On Radar Watch As 5 Potential Catalysts Could Draw Serious Buzz
September 23rd Greetings, Friend!
Biotech is racing forward, but only a handful of companies are truly standing out by going after big health challenges with brave, original approaches.
One of them is breaking new ground with a dissolvable microneedle patch designed to deliver chemotherapy straight into tumors.
The idea is to transform the way skin cancers like basal cell carcinoma are treated—offering patients an option that’s less invasive than surgery and easier to manage than conventional drug treatments.
This innovation is already under clinical study in both the U.S. and the UAE, marking the start of a potential shift in oncology.
And beyond that, the company is expanding through acquisition—most recently snapping up a late-stage UK biotech developing advanced therapies for prostate disease.
Taken together, these moves point to something larger: an effort to change how multiple diseases are treated, where safer, more effective solutions are still missing.
With a foundation in strong research and broad industry relationships, momentum toward both clinical adoption and commercial rollout seems ready to build.
Add in the fact that it has a float of fewer than 3Mn shares, a fresh acquisition just closed, and analyst targets suggesting meaningful upside potential—and it’s easy to see why this Nasdaq profile is catching attention.
For perspective, after an alert last month, this profile jumped approximately 28%, climbing from an August 18th open of $2.10 to touch $2.69 in a few weeks.
With a jump to over $3.00+ on Tuesday, it has now maxed out a move of roughly 45% and has become a Nasdaq name to think about taking a closer look at.
Take a moment to consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar.
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents.
Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX)
Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents.
Specialty: Moving innovative therapies quickly through clinical stages.
About SkinJect (Medicus Pharma's Wholly Owned Subsidiary)
Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma.
Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment.
Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016.
Clinical Progress
Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses.
Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites.
Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients.
SkinJect Value Proposition
Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors.
Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030.
Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise.
Leadership: Experienced management and board with oncology and drug development expertise.
Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones.
Find Sources Here: MDCX Presentation. MDCX Website. -----
5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark!
#1. A Low Float Scenario: With roughly 2.56Mn shares in its float, volatility potential could be heightened at the drop of a hat.
#2. Two Analyst Targets Suggest MDCX May Be Undervalued.
Take a look at this info found over at MarketBeat: | 
